Similar articles for PMID: 21355448

Year	Number of Results
1991	2
1993	1
1995	2
1996	3
1997	1
1998	4
1999	6
2000	8
2001	3
2002	3
2003	4
2004	4
2005	3
2006	8
2007	3
2008	3
2009	7
2010	7
2011	6
2012	8
2013	10
2014	9
2015	9
2016	8
2017	14
2018	12
2019	9
2020	12
2021	10
2022	7
2024	0

1

Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.

Leban J, Vitt D. Leban J, et al. Arzneimittelforschung. 2011;61(1):66-72. doi: 10.1055/s-0031-1296169. Arzneimittelforschung. 2011. PMID: 21355448 Review.

2

Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.

Herrmann ML, Schleyerbach R, Kirschbaum BJ. Herrmann ML, et al. Immunopharmacology. 2000 May;47(2-3):273-89. doi: 10.1016/s0162-3109(00)00191-0. Immunopharmacology. 2000. PMID: 10878294 Review.

3

Mechanism of action for leflunomide in rheumatoid arthritis.

Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ. Fox RI, et al. Clin Immunol. 1999 Dec;93(3):198-208. doi: 10.1006/clim.1999.4777. Clin Immunol. 1999. PMID: 10600330 Review.

4

Biaryl analogues of teriflunomide as potent DHODH inhibitors.

Erra M, Moreno I, Sanahuja J, Andrés M, Reinoso RF, Lozoya E, Pizcueta P, Godessart N, Castro-Palomino JC. Erra M, et al. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7268-72. doi: 10.1016/j.bmcl.2011.10.052. Epub 2011 Oct 20. Bioorg Med Chem Lett. 2011. PMID: 22078215

5

1,2,5-Oxadiazole analogues of leflunomide and related compounds.

Giorgis M, Lolli ML, Rolando B, Rao A, Tosco P, Chaurasia S, Marabello D, Fruttero R, Gasco A. Giorgis M, et al. Eur J Med Chem. 2011 Jan;46(1):383-92. doi: 10.1016/j.ejmech.2010.10.029. Epub 2010 Nov 3. Eur J Med Chem. 2011. PMID: 21109332

6

Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase.

Zhu J, Han L, Diao Y, Ren X, Xu M, Xu L, Li S, Li Q, Dong D, Huang J, Liu X, Zhao Z, Wang R, Zhu L, Xu Y, Qian X, Li H. Zhu J, et al. J Med Chem. 2015 Feb 12;58(3):1123-39. doi: 10.1021/jm501127s. Epub 2015 Jan 26. J Med Chem. 2015. PMID: 25580811

7

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.

Kuo EA, Hambleton PT, Kay DP, Evans PL, Matharu SS, Little E, McDowall N, Jones CB, Hedgecock CJ, Yea CM, Chan AW, Hairsine PW, Ager IR, Tully WR, Williamson RA, Westwood R. Kuo EA, et al. J Med Chem. 1996 Nov 8;39(23):4608-21. doi: 10.1021/jm9604437. J Med Chem. 1996. PMID: 8917650

8

Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.

Hurt DE, Sutton AE, Clardy J. Hurt DE, et al. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1610-5. doi: 10.1016/j.bmcl.2005.12.029. Epub 2006 Jan 10. Bioorg Med Chem Lett. 2006. PMID: 16406782

9

Mechanism of action of leflunomide in rheumatoid arthritis.

Fox RI. Fox RI. J Rheumatol Suppl. 1998 Jul;53:20-6. J Rheumatol Suppl. 1998. PMID: 9666414 Review.

10

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.

Lolli ML, Sainas S, Pippione AC, Giorgis M, Boschi D, Dosio F. Lolli ML, et al. Recent Pat Anticancer Drug Discov. 2018;13(1):86-105. doi: 10.2174/1574892812666171108124218. Recent Pat Anticancer Drug Discov. 2018. PMID: 29119937 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

175 results

Results by year